Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Baricitinib in Systemic Lupus Erythematosus
jRCT2080224034Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (3 arms), sponsored by Eli Lilly and Company. Started Sep 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080224034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224034.